SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* KDev Investments AB (Last) (First) (Middle) TOMTEBODAVAGEN 23A (Street) SOLNA V7 SE-17165 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Aprea Therapeutics, Inc. [ APRE ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 10/07/2019
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	10/07/2019		C		1,600,559	A	$0(2)	2,444,837	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock(1)	(2)	10/07/2019		C			579,647	(2)	(2)	Common Stock	579,647	$0(2)	0	I	See footnote(3)
Series B Convertible Preferred Stock(1)	(2)	10/07/2019		C			590,445	(2)	(2)	Common Stock	590,445	$0(2)	0	I	See footnote(3)
Series C Convertible Preferred Stock(1)	(2)	10/07/2019		C			430,467	(2)	(2)	Common Stock	430,467	$0(2)	0	I	See footnote(3)

1. Name and Address of Reporting Person* KDev Investments AB (Last) (First) (Middle) TOMTEBODAVAGEN 23A (Street) SOLNA V7 SE-17165 (City) (State) (Zip)

1. Name and Address of Reporting Person* Karolinska Development AB (Last) (First) (Middle) TOMTEBODAVAGEN 23A (Street) SOLNA V7 SE-17165 (City) (State) (Zip)

1. Name and Address of Reporting Person* KCIF Co-Investment Fund KB (Last) (First) (Middle) TOMTEBODAVAGEN 23A (Street) SOLNA V7 SE-17165 (City) (State) (Zip)

Explanation of Responses:

1. The amount of securities of Aprea Therapeutics, Inc. (the "Issuer") reported as beneficially owned includes shares held of record by: KDev Investments AB, Karolinska Development AB and KCIF Co-Investment Fund KB (collectively, the "Reporting Persons").

2. Shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.001, on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

3. Karolinska Development AB ("Karolinska") is the majority owner and co-manager of KDev Investments AB and a limited partner of KCIF Co-Investment Fund KB. Karolinska and each of the other Reporting Persons disclaim beneficial ownership of any shares of the Issuer's Common Stock owned of record by any of the other Reporting Persons except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that any such entity is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The address of each of (i) KDev Investments AB, (ii) Karolinska Development AB, and (iii) KCIF Co-Investment Fund KB is Tomtebodavagen 23A, SE 171 65 Solna, Sweden.

Remarks:

	KDev Investments AB By: /s/ Ulf Richenberg, attorney-in-fact	10/07/2019
	Karolinska Development AB By: /s/ Ulf Richenberg, attorney-in-fact	10/07/2019
	KCIF Co-Investment Fund KB By: /s/ Ulf Richenberg	10/07/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.